Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Inter RAO reported for 6 months of 2023 by RAS

7/26/23 IRAO

Deliveries of new Superjet aircraft postponed by half a year

7/26/23 IRKT

Irkut Corporation received the name Yakovlev

7/26/23 IRKT

Unipro's output in the first half increased by 4.4%

7/26/23 UPRO

En+ Group reported for 6 months of 2023 by RAS

7/26/23 ENPG

TGC-1 reported for 6 months of 2023 by RAS

7/26/23 TGKA

Polyus has collected applications for participation in the repurchase of shares

7/26/23 PLZL

Magnit shareholders agreed to sell to the company 21.5% of its shares

7/26/23 MGNT

Mordovenergosbyt reported for 6 months of 2023

7/26/23 MRSB

Boeing has reported for 6 months of 2023

7/26/23 BA